Similar articles

• Myocardial remodeling in diabetic cardiomyopathy associated with cardiac mast cell activation.

  Huang ZG, Jin Q, Fan M, Cong XL, Han SF, Gao H, Shan Y. Huang ZG, et al. PLoS One. 2013;8(3):e60827. doi: 10.1371/journal.pone.0060827. Epub 2013 Mar 29. PLoS One. 2013. Retraction in: PLoS One. 2024 Jun 11;19(6):e0305584. doi: 10.1371/journal.pone.0305584. PMID: 23556005 Free PMC article. Retracted.
• The emerging prominence of the cardiac mast cell as a potent mediator of adverse myocardial remodeling.

  Janicki JS, Brower GL, Levick SP. Janicki JS, et al. Methods Mol Biol. 2015;1220:121-39. doi: 10.1007/978-1-4939-1568-2_8. Methods Mol Biol. 2015. PMID: 25388248 Free PMC article.
• Cannabinoid receptor 2 activation alleviates diabetes-induced cardiac dysfunction, inflammation, oxidative stress, and fibrosis.

  Rajesh M, Mukhopadhyay P, Bátkai S, Arif M, Varga ZV, Mátyás C, Paloczi J, Lehocki A, Haskó G, Pacher P. Rajesh M, et al. Geroscience. 2022 Jun;44(3):1727-1741. doi: 10.1007/s11357-022-00565-9. Epub 2022 Apr 22. Geroscience. 2022. PMID: 35460032 Free PMC article.
• Cardiac mast cells: the centrepiece in adverse myocardial remodelling.

  Levick SP, Meléndez GC, Plante E, McLarty JL, Brower GL, Janicki JS. Levick SP, et al. Cardiovasc Res. 2011 Jan 1;89(1):12-9. doi: 10.1093/cvr/cvq272. Epub 2010 Aug 24. Cardiovasc Res. 2011. PMID: 20736239 Free PMC article. Review.
• SIRT6: A potential therapeutic target for diabetic cardiomyopathy.

  Wu T, Qu Y, Xu S, Wang Y, Liu X, Ma D. Wu T, et al. FASEB J. 2023 Aug;37(8):e23099. doi: 10.1096/fj.202301012R. FASEB J. 2023. PMID: 37462453 Review.